Biomedical engineers refined the cell-free enzyme synthesis cascade, achieving a fivefold increase in RNA yield per reaction volume while cutting reagent manufacturing costs by forty percent.
Health economists noted that cost-effective production methods will make cutting-edge mRNA immunotherapies economically viable for developing healthcare systems.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.news2026.example.com/vaccine-tech-27